INmune Bio announces publication on INKmune

INmune Bio announced the publication of our landmark paper in Journal Immunotherapy of Cancer co-authored by Mark Lowdell, PhD, INmune’s Chief Scientific Officer, titled, ” Proteomic and phenotypic characteristics of memory-like Natural Killer cells for cancer immunotherapy.” The study demonstrates that memory-like natural killer cells, generated by either cytokine or INKmune priming, show increased cytotoxicity against multiple tumor types, offering promising potential for cancer immunotherapy. Importantly, while most studies are conducted on NK cells from healthy volunteers, this study demonstrated that mlNK from cancer patients are equally as potent as those generated from healthy volunteers further supporting INKmune’s in vivo treatment methodology. The research also provides new insights into the metabolic and physiological mechanisms underlying NK cell memory, paving the way for innovative treatments in both hematological malignancies and solid tumors. Most significantly, this study is the first to demonstrate in vivo generation of mlNK cells; something which cannot be done with the cytokine cocktail used in vitro. The researchers successfully showed that these mlNK cells, primed by INKmune, can be found in patients after treatment, a critical step in proving our claimed mechanism of action. Additionally, the paper highlights the enhanced metabolic function of the NK cells primed by INKmune, predicting improved performance in the tumor microenvironment. INmune Bio is currently conducting a trial of INKmune in the treatment of metastatic castration-resistant prostate cancer. Preliminary results from that trial are expected later this year.